Division of Gastroenterology, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Meram, Konya, Turkey.
Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Konya, Turkey.
J Gastrointest Cancer. 2021 Jun;52(2):666-675. doi: 10.1007/s12029-020-00448-2.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Inflammatory and hematological parameters such as neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) provided useful information especially in the diagnosis, treatment, and follow-up of malignancies. In this study, we planned to demonstrate the efficacy of NLR and PLR levels in the evaluation of the prognosis of patients with HCC in our clinic.
This study was planned as a prospective observational cohort study. The study included 105 patients with HCC on the base of cirrhosis. Our study group was classified according to Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria at the time of admission.
The mean age of all cases was 60.6 ± 12.4 years, and 77 (73.3%) of the patients were male. The mean life expectancy of all patients was 7.7 ± 4.3 months. During 1-year follow-up, 61 (58.1%) HCC patients died. The mean survival of the patients who died was 4.6 ± 3.0 months. In our study, patients with NLR > 2.7, patients with PLR > 100.29, BCLC advanced stage, and Okuda advanced stage, and patients who did not meet the Milan criteria had shorter survival duration. NLR > 2.7, BCLC advanced stage, and Child C were determined as independent risk factors affecting mortality.
There was a strong correlation between NLR-PLR levels and mortality. PLR and NLR levels can be used in conjunction with other staging systems to regulate, monitor, and predict the survival of HCC patients.
肝细胞癌（HCC）是最常见的恶性肿瘤之一。炎症和血液学参数，如中性粒细胞/淋巴细胞比值（NLR）和血小板/淋巴细胞比值（PLR），提供了有用的信息，尤其是在恶性肿瘤的诊断、治疗和随访中。在本研究中，我们计划证明 NLR 和 PLR 水平在评估我们诊所 HCC 患者预后中的疗效。
本研究计划为前瞻性观察队列研究。该研究纳入了 105 例基于肝硬化的 HCC 患者。我们的研究组根据巴塞罗那临床肝癌（BCLC）、Okuda 分期系统和米兰标准在入院时进行分类。
所有病例的平均年龄为 60.6±12.4 岁，77 例（73.3%）为男性。所有患者的平均预期寿命为 7.7±4.3 个月。在 1 年的随访期间，有 61 例（58.1%）HCC 患者死亡。死亡患者的平均生存时间为 4.6±3.0 个月。在我们的研究中，NLR>2.7、PLR>100.29、BCLC 晚期和 Okuda 晚期以及不符合米兰标准的患者生存时间更短。NLR>2.7、BCLC 晚期和 Child C 被确定为影响死亡率的独立危险因素。
NLR-PLR 水平与死亡率之间存在很强的相关性。PLR 和 NLR 水平可以与其他分期系统一起用于调节、监测和预测 HCC 患者的生存。
